JPRN-UMIN000005246
Completed
Phase 1
Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer - Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer
Mie University Graduate School of Medicine0 sites12 target enrollmentMarch 14, 2011
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Mie University Graduate School of Medicine
- Enrollment
- 12
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Past history of severe hypersensitivity. 2\)Positive for HBs antigen, HCV antibody or HIV antibody. 3\)Experience of autoimmune disease requiring treatment during 6 months preceding the day of consent. 4\)Active multiple primaries. Simultaneous or metachronous with disease\-free interval of 5 years or more. 5\)Patient with disease requiring emergent radiotherapy. 6\)Use of steroids (more than 20 mg equivalent of prednisolone/day) or immunosup\-pressive drugs. 7\)Patients with severe complication(s). 8\)History of other NY\-ESO\-1\-related immunotherapy. 9\)Pregnant, lactating, or unprotected female. 10\)Any other cases that the attending doctor judges not appropriate to enroll to this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancerRefractory esophageal cancerJPRN-UMIN000007961Kyoto Prefectural University of Medicine18
Completed
Phase 1
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
Not yet recruiting
Not Applicable
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
Completed
Not Applicable
The phase I clinical study about the combined therapy, high purity natural killer (NK) cell therapy and IgG1 antibody to inoperable advance and recurrence digestive cancerJPRN-UMIN000013378Kyoto Prefectural University of Medicine9
Completed
Not Applicable
A study to evaluate the safety and tolerability of doxorubicin and durvalumab, in patients with advanced soft tissue sarcoma.KCT0003577Yonsei University Health System, Severance Hospital45